Oral Session

Oral Session 2-14B Gene-modified T Cell Therapy

Sat. Oct 12, 2019 10:10 AM - 11:10 AM No.14 (Tokyo International Forum, 6F G610)

Chair: Yoshiki Akatsuka (Department of Immunology, Graduate School of Medicine, Nagoya University)

+Add all to schedule

[OS2-14B-1] Development of novel CD19 CAR-T cell therapy with enhanced antitumor effect for B cell malignancies

Hiroshi Miwa¹, Hiroshi Fujiwara¹, Yasushi Akahori¹, Linan Wang¹, Satoshi Okumura¹, Yoshimasa Tanaka², Takuma Kato¹, Yoshihiro Miyahara¹, Hiroshi Shiku¹ (1.Personalized Cancer Immunotherapy, Mie Univ., Japan, 2.Center for Bioinformatics and Molecular Medicine, Nagasaki Univ., Japan)

[OS2-14B-2] HTLV-1 p40Tax-specific TCR gene-modified allogeneic γ/δ-T cells against adult T-cell leukemia

Hiroshi Fujiwara¹, Keisuke Fuji¹, Satoshi Okumura¹, Linan Wang¹, Isao Tawara², Yoshihiro Miyahara¹, Yasushi Akahori¹, Tatsuro Jo³, Yoshimasa Tanaka⁴, Hiroaki Ikeda⁵, Hiroshi Shiku^1,5 (1.Dept. Personalized Cancer Immunother., Mie Univ., Tsu, Japan, 2.Dept., Hematol., Mie Univ., Hosp., 3.Nagasaki Genbaku Hosp., 4.Ctr., Bioinform., Mol., Med, Nagasaki Univ., 5.Dpt., Oncol., Nagasaki Univ.)

[OS2-14B-3] The manufacturing process of CD19 CAR-T in r/r B-cell lymphoma - the experience of a single center

Ken Ohmine^1,2, Ryosuke Uchibori², Kento Umino¹, Ikuei Nukaya⁴, Daisuke Tomura⁴, Hirotomo Nakashima¹, Takashi Ikeda¹, Yumiko Toda¹, Shinichiro Kawaguchi¹, Shoko Ito¹, Daisuke Minakata¹, Hirofumi Nakano¹, Shinichi Ochi¹, Takashi Nagayama¹, Kiyomi Mashima¹, Ryoko Yamasaki¹, Kaoru Morita¹, Masahiro Ashizawa¹, Kaoru Hatano¹, Masuzu Ueda¹, Kazuya Sato¹, Iekuni Oh¹, Shinichiro Fujiwara¹, Kiyoshi Okazuka⁵, Kazuo Muroi³, Junichi Mineno⁴, Yoshinobu Kanda¹, Keiya Ozawa² (1.Div. of Hematol, Jichi Medical Univ., Tochigi, Japan, 2.Immuno-Gene and Cell Therapy (Takara Bio), Jichi Medical Univ., 3.Div. of Cell Transplantation and Transfusion, Jichi Medical Univ. Hosp., 4.Takara Bio Inc., Kusatsu, Japan, 5.Japanese Red Cross Medical Center, Tokyo, Japan)

[OS2-14B-4] The utility and safety of new chimeric antigen receptor T cell therapy targeting CD37

Shingo Okuno^1,2, Seitaro Terakura¹, Jakrawadee Julamanee¹, Toshiyasu Sakai¹, Nobuhiko Imahashi¹, Tetsuya Nishida¹, Makoto Murata¹, Hitoshi Kiyoi¹ (1.Hematology and Oncology, Nagoya University, Aichi, Japan, 2.Hematology and Oncology, Tosei general hospital, Aichi, Japan)

[OS2-14B-5] Two-step strategy for establishing genome-edited T cells for safer T cell adoptive immunotherapy

Takakazu Kawase¹, Yasuko Honjo¹, Kayo Toishigawa¹, Takahiko Miyama¹, Hiroyuki Sato², Ryuji Suzuki², Tetsushi Sakuma³, Takashi Yamamoto³, Tatsuo Ichinohe¹ (1.Dept. Hematol. and Oncol, Hiroshima Univ. RIRBM, Hiroshima, Japan, 2.Repertoire Genesis Incorporation, Ibaraki, Japan, 3.Grad. Sch. Integr. Sci. for Life, Hiroshima Univ., Higashi-Hiroshima, Japan)

[OS2-14B-6] Immunotherapeutic strategies to treat chronic norovirus infection in immunocompromised patients

Ryo Hanajiri^1,2, Gelina Sani², Patrick Hanley², Kim Green³, Jeffrey Cohen³, Michael Keller², Catherine Bollard² (1.Department of Hematology and Oncology, Nagoya University, Nagoya, Japan, 2.Children's National Medical Center, Washington DC, USA, 3.National Institutes of Health, Bethesda, MD, USA)